Get started
Author

Etienne Jousseaume

Observed name: E. Jousseaume
Observed institution: Novartis (Switzerland)
OpenAlex ID: A5030804181
A Retrospective Cohort Study of Treatment Outcomes of Adult Patients With Relapsed or Refractory Follicular Lymphoma (ReCORD-FL)
2022 · Gilles Salles, Stephen J. Schuster, et al. · HemaSphere · 32
Assessment of Healthcare Resource Utilization and Hospitalization Costs in Patients With Relapsed or Refractory Follicular Lymphoma Undergoing CAR-T Cell Therapy With Tisagenlecleucel: Results From the ELARA Study
2022 · Nathan Hale Fowler, Michael Dickinson, et al. · Transplantation and Cellular Therapy · 19
Tisagenlecleucel vs. historical standard of care in children and young adult patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia
2023 · Arend v. Stackelberg, Katja Jäschke, et al. · Leukemia · 13
PDF
Comparative efficacy and safety of tisagenlecleucel and axicabtagene ciloleucel among adults with r/r follicular lymphoma
2024 · Michael Dickinson, Joaquin Martinez-Lopez, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 11
Assessment of Healthcare Resource Utilization and Costs in Patients with Relapsed or Refractory Follicular Lymphoma Undergoing CAR-T Cell Therapy with Tisagenlecleucel: Results from the Elara Study
2021 · Nathan H. Fowler, Michael Dickinson, et al. · Blood · 6
Matching-Adjusted Indirect Comparison of Efficacy and Safety for Tisagenlecleucel and Mosunetuzumab in Patients (pts) with Relapsed/Refractory Follicular Lymphoma (r/r FL)
2023 · Nathan H. Fowler, Stephen J. Schuster, et al. · Transplantation and Cellular Therapy · 4
A Retrospective Cohort Study of Treatment Outcomes of Adult Patients with Relapsed or Refractory Low-Grade Follicular Lymphoma (ReCORD-FL)
2021 · Gilles Salles, Stephen J. Schuster, et al. · Blood · 4
Pcn72 - Budget Impact Analysis of Tisagenlecleucel for the Treatment of Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma in England
2018 · S. Hollmann, C. Painter, et al. · Value in Health · 4
PDF
Pcn68 - Budget Impact Analysis of Tisagenlecleucel for the Treatment of Paediatric and Young Adult Patients With Relapsed or Refractory B-cell Acute Lymphoblastic Leukaemia in England
2018 · S. Hollmann, C. Painter, et al. · Value in Health · 4
P1111: Comparative Efficacy and Safety of Tisagenlecleucel and Axicabtagene Ciloleucel in Relapsed/refractory Follicular Lymphoma
2022 · M. Dickinson, J. Martinez-Lopez, et al. · HemaSphere · 3
PCN206 Evaluating Patient Experiences in Follicular Lymphoma (FL) through Social Media Listening (SML) Research from Five Countries in North America and Europe
2021 · P. Arun, Q. Ma, et al. · Value in Health · 2
Comparative Efficacy and Safety of Tisagenlecleucel (tisa-cel) and Axicabtagene Ciloleucel (axi-cel) in Relapsed/ Refractory Follicular Lymphoma (r/r FL)
2022 · Michael Dickinson, Joaquin Martinez-Lopez, et al. · Transplantation and Cellular Therapy · 1
244 | Tisagenlecleucel Versus Mosunetuzumab in Relapsed/refractory Follicular Lymphoma: a Matching‐adjusted Indirect Comparison Using 3‐year Follow‐up Data
2025 · N. H. Fowler, S. J. Schuster, et al. · Hematological Oncology
PDF
Assessment of Healthcare Resource Utilization (HCRU) and Hospitalization Costs in Patients (pts) with Relapsed or Refractory (r/r) Follicular Lymphoma (FL) Undergoing CAR-T Cell Therapy with Tisagenlecleucel: Results from the Elara Study
2022 · Nathan H. Fowler, Michael Dickinson, et al. · Transplantation and Cellular Therapy
Treatment Regimens and Clinical Outcomes Among Follicular Lymphoma Patients Treated with Third-Line Therapy in the United States: A Real-World EHR Study
2021 · Dong Dai, Ji Haeng Heo, et al. · Blood
Commercialising CAR-T Therapies
2020 · Emanuele Ostuni, Bernd Eschgfaeller, et al. · Elsevier eBooks
List of Contributors
2020 · Julie G. Allickson, Rafael G. Amado, et al. · Elsevier eBooks
Pbi18 Estimation of the Healthcare Resource Utilization (hcru) Costs in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma Receiving Tisagenlecleucel: a Micro-costing Study in the Uk and France
2019 · H. Yang, Q. Ma, et al. · Value in Health
PDF
Works count: 18
Citation count: 103
H-index: 5
I10-index: 4
Year
Topic
Type